RATIONALE: The effectiveness of cannabidiolic acid (CBDA) was compared with other potential treatments for anticipatory nausea (AN), using a rat model of contextually elicited conditioned gaping reactions. OBJECTIVE: The potential of ondansetron (OND), Δ(9)-tetrahydrocannabinol (THC), chlordiazepoxide (CDP), CBDA, and co-administration of CBDA and tetrahydrocannabinolic acid (THCA) to reduce AN and modify locomotor activity was evaluated. MATERIALS AND METHODS: Following four pairings of a novel context with lithium chloride (LiCl), the rats were given a test for AN. On the test trial, they received pretreatment injections of the following: vehicle, OND (0.1 or 1.0 mg/kg), THC (0.5 mg/kg), CBDA (0.0001, 0.001, 0.01, 0.1 mg/kg or 1.0 mg/kg), CDP (1, 5, or 10 mg/kg) or co-administration of subthreshold doses of CBDA (0.1 μg/kg), and THCA (5 μg/kg). Immediately following the AN test trial in all experiments, rats were given a 15 min locomotor activity test. Finally, the potential of CBDA (0.001, 0.01, 0.1, and 1 mg/kg) to attenuate conditioned freezing to a shock-paired tone was assessed. RESULTS: THC, CBDA, and CDP, but not OND, reduced contextually elicited gaping reactions. Co-administration of subthreshold doses of CBDA and THCA also suppressed AN, and this effect was blocked by pretreatment with either a cannabinoid receptor 1 (CB1) receptor antagonist or a 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist. CDP (but not CBDA, THC or CBDA and THCA) also suppressed locomotor activity at effective doses. CBDA did not modify the expression of conditioned fear. CONCLUSIONS: CBDA has therapeutic potential as a highly potent and selective treatment for AN without psychoactive or locomotor effects.
RATIONALE: The effectiveness of cannabidiolic acid (CBDA) was compared with other potential treatments for anticipatory nausea (AN), using a rat model of contextually elicited conditioned gaping reactions. OBJECTIVE: The potential of ondansetron (OND), Δ(9)-tetrahydrocannabinol (THC), chlordiazepoxide (CDP), CBDA, and co-administration of CBDA and tetrahydrocannabinolic acid (THCA) to reduce AN and modify locomotor activity was evaluated. MATERIALS AND METHODS: Following four pairings of a novel context with lithium chloride (LiCl), the rats were given a test for AN. On the test trial, they received pretreatment injections of the following: vehicle, OND (0.1 or 1.0 mg/kg), THC (0.5 mg/kg), CBDA (0.0001, 0.001, 0.01, 0.1 mg/kg or 1.0 mg/kg), CDP (1, 5, or 10 mg/kg) or co-administration of subthreshold doses of CBDA (0.1 μg/kg), and THCA (5 μg/kg). Immediately following the AN test trial in all experiments, rats were given a 15 min locomotor activity test. Finally, the potential of CBDA (0.001, 0.01, 0.1, and 1 mg/kg) to attenuate conditioned freezing to a shock-paired tone was assessed. RESULTS:THC, CBDA, and CDP, but not OND, reduced contextually elicited gaping reactions. Co-administration of subthreshold doses of CBDA and THCA also suppressed AN, and this effect was blocked by pretreatment with either a cannabinoid receptor 1 (CB1) receptor antagonist or a 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist. CDP (but not CBDA, THC or CBDA and THCA) also suppressed locomotor activity at effective doses. CBDA did not modify the expression of conditioned fear. CONCLUSIONS:CBDA has therapeutic potential as a highly potent and selective treatment for AN without psychoactive or locomotor effects.
Authors: E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: Charles Kamen; Mohamedtaki A Tejani; Kavita Chandwani; Michelle Janelsins; Anita R Peoples; Joseph A Roscoe; Gary R Morrow Journal: Eur J Pharmacol Date: 2013-10-21 Impact factor: 4.432
Authors: Cheryl L Limebeer; Jon P Krohn; Shelley Cross-Mellor; Devin E Litt; Klaus-Peter Ossenkopp; Linda A Parker Journal: Behav Brain Res Date: 2007-08-25 Impact factor: 3.332
Authors: Daniel I Brierley; James Samuels; Marnie Duncan; Benjamin J Whalley; Claire M Williams Journal: Psychopharmacology (Berl) Date: 2015-10-06 Impact factor: 4.530
Authors: Cheryl L Limebeer; Erin M Rock; Nirushan Puvanenthirarajah; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Behav Neurosci Date: 2016-04 Impact factor: 1.912
Authors: Roger G Pertwee; Erin M Rock; Kelsey Guenther; Cheryl L Limebeer; Lesley A Stevenson; Christeene Haj; Reem Smoum; Linda A Parker; Raphael Mechoulam Journal: Br J Pharmacol Date: 2017-12-05 Impact factor: 8.739